Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors.

Intravesical BCG is the gold-standard therapy for non-muscle invasive bladder cancer (NMIBC); however, it still fails in a significant proportion of patients, so improved treatment options are urgently needed.

Here, we compared BCG antitumoral efficacy with another live attenuated mycobacteria, MTBVAC, in an orthotopic mouse model of bladder cancer (BC). We aimed to identify both bacterial and host immunological factors to understand the antitumoral mechanisms behind effective bacterial immunotherapy for BC.

We found that the expression of the BCG-absent proteins ESAT6/CFP10 by MTBVAC was determinant in mediating bladder colonization by the bacteria, which correlated with augmented antitumoral efficacy. We further analyzed the mechanism of action of bacterial immunotherapy and found that it critically relied on the adaptive cytotoxic response. MTBVAC enhanced both tumor antigen-specific CD4+ and CD8+ T-cell responses, in a process dependent on stimulation of type 1 conventional dendritic cells. Importantly, improved intravesical bacterial immunotherapy using MBTVAC induced eradication of fully established bladder tumors, both as a monotherapy and specially in combination with the immune checkpoint inhibitor antiprogrammed cell death ligand 1 (anti PD-L1).

These results contribute to the understanding of the mechanisms behind successful bacterial immunotherapy against BC and characterize a novel therapeutic approach for BCG-unresponsive NMIBC cases.

Journal for immunotherapy of cancer. 2022 Jul [Epub]

Eduardo Moreo, Santiago Uranga, Ana Picó, Ana Belén Gómez, Denise Nardelli-Haefliger, Carlos Del Fresno, Ingrid Murillo, Eugenia Puentes, Esteban Rodríguez, Mar Vales-Gómez, Julian Pardo, David Sancho, Carlos Martín, Nacho Aguilo

Departamento de Microbiología, Pediatría, Radiología y Salud Pública, Universidad de Zaragoza/IIS Aragon, Zaragoza, Spain., Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland., Hospital la Paz Institute for Health Research, IdiPAZ, Madrid, Spain., Grupo Zendal, Pontevedra, Spain., Departamento de Inmunología y Oncología, CNB-CSIC, Madrid, Spain., CIBERES, CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain., Immunobiology Lab, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain., Departamento de Microbiología, Pediatría, Radiología y Salud Pública, Universidad de Zaragoza/IIS Aragon, Zaragoza, Spain .

Go Beyond the Abstract and Read a Commentary by the Authors

email news signup